Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 5/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853485 | 0.91 | NPC1 (0.51) | ALDH1A1NPC1RAB9A | |
| SCHEMBL5462314 | 0.88 | NPC1 (0.56) | NPC1RAB9AEPHX2CTSVCTSL | |
| SCHEMBL6168123 | 0.85 | P2RX7 (0.50) | CCR1ALDH1A1NPC1RAB9ACTSV | |
| SCHEMBL5453401 | 0.85 | ACKR3 (0.46) | ALDH1A1PIN1CTSL | |
| SCHEMBL2857688 | 0.85 | MEN1 (0.66) | ALDH1A1NPC1RAB9ACTSLCTSS | |
| SCHEMBL2859751 | 0.85 | ACKR3 (0.49) | ALDH1A1PIN1 | |
| SCHEMBL2867569 | 0.84 | MEN1 (0.54) | ALDH1A1 | |
| SCHEMBL2877086 | 0.83 | EPHX2 (0.61) | ALDH1A1NPC1RAB9AEPHX2ACE | |
| SCHEMBL2861403 | 0.83 | L3MBTL1 (0.49) | ALDH1A1NPC1RAB9AEPHX2ACE | |
| SCHEMBL8179465 | 0.82 | MAPT (0.50) | CCR1ALDH1A1NPC1RAB9ACTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | CTRB1 4455/4885CCR1 4361/4885ALDH1A1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.